Peter de Blank1,2, Pratiti Bandopadhayay3,4,5, Daphne Haas-Kogan4,6, Maryam Fouladi1,2, Jason Fangusaro7,8. 1. University of Cincinnati. 2. Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. 4. Harvard Medical School. 5. Broad Institute of MIT and Harvard, Boston, Massachusetts. 6. Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital. 7. Division of Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta. 8. Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: Pediatric low-grade gliomas (pLGGs) have been treated with similar therapies for the last 30 years. Recent biological insights have allowed a new generation of targeted therapies to be developed for these diverse tumors. At the same time, technological advances may redefine the late toxicities associated with radiation therapy. Understanding recent developments in pLGG therapy is essential to the management of these common pediatric tumors. RECENT FINDINGS: It is now well understood that aberrations of the mitogen-activated protein kinase pathway are key to oncogenesis in low-grade gliomas. This understanding, along with the development of available targeted agents, have heralded a new era of understanding and treatment for these patients. Promising, sustained responses are now being seen in early phase trials among patients with multiply recurrent/progressive disease. Also, newer and highly conformal radiation approaches such as proton beam radiotherapy maintain efficacy of radiation but limit radiation-associated toxicities. SUMMARY: Novel therapies offer the potential for tumor control with greatly reduced toxicities. However, late effects of these therapies are just now being explored. Improved radiation approaches and targeted agents have the potential to redefine traditional therapy for pLGG.
PURPOSE OF REVIEW: Pediatric low-grade gliomas (pLGGs) have been treated with similar therapies for the last 30 years. Recent biological insights have allowed a new generation of targeted therapies to be developed for these diverse tumors. At the same time, technological advances may redefine the late toxicities associated with radiation therapy. Understanding recent developments in pLGG therapy is essential to the management of these common pediatric tumors. RECENT FINDINGS: It is now well understood that aberrations of the mitogen-activated protein kinase pathway are key to oncogenesis in low-grade gliomas. This understanding, along with the development of available targeted agents, have heralded a new era of understanding and treatment for these patients. Promising, sustained responses are now being seen in early phase trials among patients with multiply recurrent/progressive disease. Also, newer and highly conformal radiation approaches such as proton beam radiotherapy maintain efficacy of radiation but limit radiation-associated toxicities. SUMMARY: Novel therapies offer the potential for tumor control with greatly reduced toxicities. However, late effects of these therapies are just now being explored. Improved radiation approaches and targeted agents have the potential to redefine traditional therapy for pLGG.
Authors: Omer Sager; Ferrat Dincoglan; Selcuk Demiral; Bora Uysal; Hakan Gamsiz; Esra Gumustepe; Fatih Ozcan; Onurhan Colak; Ahmet Tarik Gursoy; Cemal Ugur Dursun; Ahmet Oguz Tugcu; Galip Dogukan Dogru; Rukiyye Arslan; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu Journal: World J Exp Med Date: 2022-05-20
Authors: Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Olivia Campagne; Anu Banerjee; Sridharan Gururangan; Lindsay B Kilburn; Stewart Goldman; Ibrahim Qaddoumi; Patricia Baxter; Gilbert Vezina; Corey Bregman; Zoltan Patay; Jeremy Y Jones; Clinton F Stewart; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 12.300
Authors: Roger J Packer; Antonio Iavarone; David T W Jones; Jaishri O Blakeley; Eric Bouffet; Michael J Fisher; Eugene Hwang; Cynthia Hawkins; Lindsay Kilburn; Tobey MacDonald; Stefan M Pfister; Brian Rood; Fausto J Rodriguez; Uri Tabori; Vijay Ramaswamy; Yuan Zhu; Jason Fangusaro; Stephen A Johnston; David H Gutmann Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel Journal: Curr Oncol Rep Date: 2021-03-15 Impact factor: 5.075
Authors: Margot A Lazow; Lindsey Hoffman; Austin Schafer; Diana S Osorio; Daniel R Boué; Sarah Rush; Erin Wright; Adam Lane; Mariko D DeWire-Schottmiller; Teresa Smolarek; Jared Sipple; Heather Taggert; Jaime Reuss; Ralph Salloum; Trent R Hummel; Peter de Blank; Natasha Pillay-Smiley; Mary E Sutton; Anthony Asher; Charles B Stevenson; Rachid Drissi; Jonathan L Finlay; Maryam Fouladi; Christine Fuller Journal: Acta Neuropathol Commun Date: 2020-11-05 Impact factor: 7.801